Form 8-K · Current report
Abbott Laboratories 8-K, filed Jul 16, 2026
- Filed
- CIK
- 0000001800
- Accession no.
- 0001628280-26-048377
Summary
Abbott Laboratories reported second-quarter 2026 sales growth of 13.0 percent on a reported basis and 4.8 percent on a comparable basis, with GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31, and raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60 from $5.38 to $5.58 while reaffirming comparable sales growth guidance of 6.5% to 7.5%. Chairman and CEO Robert B. Ford said the results reflect building momentum expected to drive accelerating sales and earnings growth in the second half of the year.
Key points
- Second-quarter sales rose 13.0 percent on a reported basis and 4.8 percent on a comparable basis, with GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31.
- Abbott reaffirmed full-year 2026 comparable sales growth guidance of 6.5% to 7.5%.
- Abbott returned $2.1 billion to shareholders in the second quarter through dividends and share repurchases.
- The company completed enrollment in the TECTONIC U.S. pivotal trial of its investigational Coronary Intravascular Lithotripsy System and secured CE Mark for Libre Duo, a dual glucose-ketone biowearable sensor.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition On July 16, 2026, Abbott Laboratories announced its results of operations for the second quarter 2026. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.